ALIMERA SCIENCES INC (ALIM)
US0162592028 - Common Stock
ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, ALIM, INFN on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
ALIM Stock Earnings: Alimera Sciences Misses EPS, Beats Revenue for Q2 2024
ALIM stock results show that Alimera Sciences missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
ALIM Stock Earnings: Alimera Sciences Misses EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alimera Sciences (NASDAQ:ALIM) just reported results for the second quarter of ...
Alimera Sciences Reports Second Quarter 2024 Results
Net Revenue up 54% to $27 Million vs. Q2 2023Global End User Demand up 6% vs. Q2 2023Company Recently Announced Definitive Merger Agreement with ANI...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, ALE on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, MORF, AGR on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SHCR, AGR on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SRDX, ATRI on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRFT, SBOW, ALIM, HCP on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SPR, AGR, AGS on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SHCR, AGRX on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SHCR, BEST, VAPO on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Kuehn Law Encourages UMBF, ALIM, TBNK, and BEST Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SBOW, AGR, RPHM on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, BEST, AGR on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders
/PRNewswire/ -- Ademi LLP is investigating Alimera (Nasdaq: ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Why Is MicroAlgo (MLGO) Stock Up 113% Today?
MicroAlgo stock is up on Monday after the company revealed in an SEC filing that an investor now holds an almost 14% stake in MLGO.
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals.
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose...
ALIM Stock Earnings: Alimera Sciences Misses EPS, Beats Revenue for Q1 2024
ALIM stock results show that Alimera Sciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
ALIM Stock Earnings: Alimera Sciences Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alimera Sciences (NASDAQ:ALIM) just reported results for the first quarter of 2...
Alimera Sciences Reports First Quarter 2024 Results
Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ...
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy...
ALIM Stock Earnings: Alimera Sciences Beats Revenue for Q4 2023
ALIM stock results show that Alimera Sciences beat on revenue for the fourth quarter of 2023.
ALIM Stock Earnings: Alimera Sciences Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alimera Sciences (NASDAQ:ALIM) just reported results for the fourth quarter of ...
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases 2024 Revenue Guidance ...